Prepared by:
Johns Hopkins University, Baltimore, MD
Robert L. McNamara, M.D., M.H.S.
Principal Investigator
Eric B. Bass, M.D., M.P.H.
Co-Principal Investigator
Marlene R. Miller, M.D.
Jodi B. Segal, M.D., M.P.H.
Steven N. Goodman, M.D., Ph.D.
Nina L. Kim, M.A.
Karen A. Robinson, M.Sc.
Neil R. Powe, M.D., M.P.H., M.B.A.
Investigators
File Name Description Software Version File Size __________________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 97 SR-1 49KB 12 pages Contents: Title Page, Preface, Structured Abstract, Table of Contents __________________________________________________________________________________________________________ 02body.doc Microsoft Word® Document MS Word® 97 SR-1 714KB 175 pages Contents: Summary, Chapter 1. Introduction, Chapter 2. Methodology, Chapter 3. Results, Chapter 4. Conclusions, Chapter 5. Future Research, Chapter 6. Decision Analysis, References __________________________________________________________________________________________________________ 03etab1.doc Microsoft Word® Document MS Word® 97 SR-1 130KB 8 pages Contents: Evidence table 1. Design Characteristics of Studies on Pharmacological Conversion (Alone and in Conjunction with Direct Current Cardioversion) of Atrial Fibrillation __________________________________________________________________________________________________________ 04etab2.doc Microsoft Word® Document MS Word® 97 SR-1 83KB 6 pages Contents: Evidence table 2. Design Characteristics of Studies on Pharmacological Maintenance of Sinus Rhythm in Atrial Fibrillation __________________________________________________________________________________________________________ 05etab3.doc Microsoft Word® Document MS Word® 97 SR-1 138KB 8 pages Contents: Evidence table 3. Results of Studies on Pharmacological Conversion of Atrial Fibrillation __________________________________________________________________________________________________________ 06etab4.doc Microsoft Word® Document MS Word® 97 SR-1 45KB 2 pages Contents: Evidence table 4. Results of Studies on Pharmacological Conversion in Conjunction with Direct Current Cardioversion of Atrial Fibrillation __________________________________________________________________________________________________________ 07etab5.doc Microsoft Word® Document MS Word® 97 SR-1 99KB 5 pages Contents: Evidence table 5. Results of Studies on Pharmacological Maintenance of Sinus Rhythm in Atrial Fibrillation __________________________________________________________________________________________________________ 08etab6a.doc Microsoft Word® Document MS Word® 97 SR-1 42KB 2 pages Contents: Evidence table 6A. Design of Placebo-Controlled Trials of Calcium-Channel-Blockers for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 09etab6b.doc Microsoft Word® Document MS Word® 97 SR-1 47KB 2 pages Contents: Evidence table 6B. Design of Placebo-Controlled Trials of Beta-Blockers for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 10etab6c.doc Microsoft Word® Document MS Word® 97 SR-1 54KB 4 pages Contents: Evidence table 6C. Design of Placebo-Controlled Trials of Other Drugs and Combinations for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 11etab6d.doc Microsoft Word® Document MS Word® 97 SR-1 41KB 2 pages Contents: Evidence table 6D. Design of Trials Comparing Calcium-Channel-Blockers to Digoxin for Rate Control for Atrial Fibrillation __________________________________________________________________________________________________________ 12etab6e.doc Microsoft Word® Document MS Word® 97 SR-1 34KB 1 page Contents: Evidence table 6E. Design of Trials Comparing Beta-Blockers to Digoxin for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 13etab6f.doc Microsoft Word® Document MS Word® 97 SR-1 62KB 4 pages Contents: Evidence table 6F. Design of Digoxin-Controlled Trials of Other Drugs or Combinations for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 14etab6g.doc Microsoft Word® Document MS Word® 97 SR-1 42KB 2 pages Contents: Evidence table 6G. Design of Trials Comparing Other Drugs for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 15etab7a.doc Microsoft Word® Document MS Word® 97 SR-1 42KB 2 pages Contents: Evidence table 7A. Results of Placebo-Controlled Trials of Calcium-Channel-Blockers for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 16etab7b.doc Microsoft Word® Document MS Word® 97 SR-1 43KB 3 pages Contents: Evidence table 7B. Results of Placebo-Controlled Trials of Beta-Blockers for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 17etab7c.doc Microsoft Word® Document MS Word® 97 SR-1 47KB 4 pages Contents: Evidence table 7C. Results of Placebo-Controlled Trials of Other Drugs or Combinations for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 18etab7d.doc Microsoft Word® Document MS Word® 97 SR-1 36KB 2 pages Contents: Evidence table 7D. Results of Trials Comparing Calcium-Channel-Blockers to Digoxin for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 19etab7e.doc Microsoft Word® Document MS Word® 97 SR-1 31KB 2 pages Contents: Evidence table 7E. Results of Trials Comparing Beta-Blockers to Digoxin for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 20etab7f.doc Microsoft Word® Document MS Word® 97 SR-1 54KB 5 pages Contents: Evidence table 7F. Results of Digoxin-Controlled Trials of Other Drugs or Combinations for Rate Control for Atrial Fibrillation __________________________________________________________________________________________________________ 21etab7g.doc Microsoft Word® Document MS Word® 97 SR-1 36KB 2 pages Contents: Evidence table 7G. Results of Trials Comparing Other Drugs for Rate Control in Atrial Fibrillation __________________________________________________________________________________________________________ 22etab8.doc Microsoft Word® Document MS Word® 97 SR-1 47KB 3 pages Contents: Evidence table 8. Designs of Studies of Antithrombotic Therapies for Patients with Atrial Fibrillation __________________________________________________________________________________________________________ 23etab9.doc Microsoft Word® Document MS Word® 97 SR-1 61KB 4 pages Contents: Evidence table 9. Results of Studies of Antithrombotic Therapies for Patients with Atrial Fibrillation __________________________________________________________________________________________________________ 24efigs.doc Microsoft Word® Document MS Word® 97 SR-1 3.3MB 70 pages Contents: Figures 1 through 62 __________________________________________________________________________________________________________ 25biblio.doc Microsoft Word® Document MS Word® 97 SR-1 197KB 36 pages Contents: Bibliography __________________________________________________________________________________________________________ 26appa.doc Microsoft Word® Document MS Word® 97 SR-1 37KB 4 pages Contents: Appendix A. Technical Experts for Evidence Report on Management of Atrial Fibrillation __________________________________________________________________________________________________________ 27appb.doc Microsoft Word® Document MS Word® 97 SR-1 49KB 4 pages Contents: Appendix B. Questionnaire Regarding New Onset Atrial Fibrillation __________________________________________________________________________________________________________ 28appc.doc Microsoft Word® Document MS Word® 97 SR-1 76KB 2 pages Contents: Appendix C. Causal Pathway of Atrial Fibrillation __________________________________________________________________________________________________________ 29appd.doc Microsoft Word® Document MS Word® 97 SR-1 35KB 2 pages Contents: Appendix D. Overall Topic Search Strategy for CENTRAL and MEDLINE __________________________________________________________________________________________________________ 30appe.doc Microsoft Word® Document MS Word® 97 SR-1 36KB 2 pages Contents: Appendix E. Cochrane Optimal Search Strategy for Retrieval of Controlled Trials __________________________________________________________________________________________________________ 31appf.doc Microsoft Word® Document MS Word® 97 SR-1 36KB 2 pages Contents: Appendix F. Additional Search Strategy for Key Question 4 __________________________________________________________________________________________________________ 32appg.doc Microsoft Word® Document MS Word® 97 SR-1 36KB 2 pages Contents: Appendix G. Additional Search Strategy for Key Question 5 __________________________________________________________________________________________________________ 33apph.doc Microsoft Word® Document MS Word® 97 SR-1 40KB 2 pages Contents: Appendix H. Abstract Review Form __________________________________________________________________________________________________________ 34appi.doc Microsoft Word® Document MS Word® 97 SR-1 119KB 26 pages Contents: Appendix I. Article Review Form __________________________________________________________________________________________________________ 35appj.doc Microsoft Word® Document MS Word® 97 SR-1 127KB 18 pages Contents: Appendix J. Article Review Form __________________________________________________________________________________________________________ 36appk.doc Microsoft Word® Document MS Word® 97 SR-1 37KB 2 pages Contents: Appendix K. List of Journals Cited More Than Twice in Atrial Fibrillation Database as of April 2, 1998, Used for REVEAL Service __________________________________________________________________________________________________________ 37appl.doc Microsoft Word® Document MS Word® 97 SR-1 37KB 2 pages Contents: Appendix L. Abstract Review __________________________________________________________________________________________________________ 38appm.doc Microsoft Word® Document MS Word® 97 SR-1 38KB 2 pages Contents: Appendix M. Article Review __________________________________________________________________________________________________________ 39appn.doc Microsoft Word® Document MS Word® 97 SR-1 42KB 4 pages Contents: Appendix N. Summary of Abstract Review Disagreements Between Reviewers __________________________________________________________________________________________________________ 40appo.doc Microsoft Word® Document MS Word® 97 SR-1 40KB 2 pages Contents: Appendix O. Articles Identified Too Late for Inclusion in Evidence Synthesis __________________________________________________________________________________________________________ 41appp.doc Microsoft Word® Document MS Word® 97 SR-1 85KB 2 pages Contents: Appendix P. Subgroup Analysis __________________________________________________________________________________________________________
AHRQ Publication No. 01-E026
Current as of January 2001
Internet Citation:
Management of New Onset Atrial Fibrillation. File Inventory, Evidence Report/Technology Assessment Number 12. AHRQ Publication No. 01-E026, January 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/atfibinv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services